ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

TOPAMAX SPRINKLE CAPS
Migraine and headache
Seizure disorders
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

TOPAMAX SPRINKLE CAPS Rx

Generic Name and Formulations:
Topiramate 15mg, 25mg; coated beads in caps.

Company:
Janssen Pharmaceuticals, Inc.

e-Prescribe this drug via Surescripts


Therapeutic Use:

Indications for TOPAMAX SPRINKLE CAPS:

Migraine prophylaxis.

Adult Dose for TOPAMAX SPRINKLE CAPS:

May swallow caps whole or sprinkle contents onto soft food (swallow immediately). Titrate in 1-week intervals. Initially 25mg once daily in the PM, then 25mg twice daily, then 25mg in the AM and 50mg in the PM, then 50mg twice daily. Renal impairment (CrCl <70mL/min): reduce dose by ½. Hemodialysis: may need extra dose.

Children's Dose for TOPAMAX SPRINKLE CAPS:

Not recommended.

See Also:

TOPAMAX TABLETS

Pharmacological Class:

Sulfamate.

Warnings/Precautions:

Discontinue if acute myopia and secondary angle-closure glaucoma occur. Hepatic or renal impairment. Kidney stones. Maintain adequate hydration and caloric intake; avoid ketogenic diets. Monitor serum bicarbonate during therapy; consider reducing dose or discontinuing if acidosis occurs. Inborn errors of metabolism, reduced mitochondrial activity: increased risk of hyperammonemia; measure ammonia levels if encephalopathic symptoms occur. Monitor closely for oligohidrosis and hyperthermia (esp. children). Suicidal tendencies (monitor). Avoid abrupt cessation. Fetal toxicity. Labor & delivery. Pregnancy (Cat.D). Nursing mothers.

Interactions:

Contraindicated with metformin during metabolic acidosis condition. Avoid concomitant other carbonic anhydrase inhibitors (eg, zonisamide, acetazolamide, dichlorphenamide). Phenytoin, carbamazepine, valproic acid, lamotrigine reduce topiramate levels. Topiramate reduces valproic acid levels. May increase phenytoin levels. May antagonize digoxin, oral contraceptives, risperidone. CNS depression potentiated with alcohol, other CNS depressants. Hyperammonemia (w/ and w/o encephalopathy) and/or hypothermia possible with valproic acid. Caution with other drugs that interfere with temperature regulation (eg, anticholinergics, carbonic anhydrase inhibitors). Monitor lithium levels with high-dose topiramate.

Adverse Reactions:

Paresthesia, anorexia, weight decrease, fatigue, dizziness, somnolence, nervousness, psychomotor slowing, difficulty with memory, difficulty with concentration/attention, cognitive problems, confusion, mood problems, fever, infection, flushing; kidney stones, hyperchloremic acidosis, hyperammonemia.

Metabolism:

Hepatic (minor).

Elimination:

Renal.

Generic Availability:

YES

How Supplied:

Tabs, caps—60

Indications for TOPAMAX SPRINKLE CAPS:

Initial monotherapy and adjunct in partial-onset or primary generalized tonic-clonic seizures. Adjunct in Lennox-Gastaut syndrome.

Adult Dose for TOPAMAX SPRINKLE CAPS:

May swallow caps whole or sprinkle contents onto soft food (swallow immediately). Give in two equally divided doses. Monotherapy: initially 50mg/day, increase at 1-week intervals by increments of 50mg/week for the 1st 4 weeks, then increase by 100mg/week for weeks 5–6 to target dose of 400mg/day. Adjunctive therapy: ≥17years: Initially 25–50mg/day, increase at 1-week intervals by 25–50mg/day every week (see literature) to target dose of 200–400mg/day (partial onset seizures or Lennox-Gastaut) or 400mg/day (primary generalized tonic-clonic seizures); usual max 1.6g/day. Renal impairment (CrCl <70mL/min): reduce dose by ½. Hemodialysis: may need extra dose.

Children's Dose for TOPAMAX SPRINKLE CAPS:

May swallow caps whole or sprinkle contents onto soft food (swallow immediately). Give in two equally divided doses. Monotherapy: <2yrs: not recommended. 2 to <10yrs: (dosing based on weight) initially 25mg/day in the PM for the 1st week, then increase to 50mg/day in the 2nd week; subsequently, may increase weekly by 25–50mg/day as tolerated. Titration to the minimum or maximum maintenance dose should be attempted over 5–7 weeks: see literature. ≥10yrs: initially 50mg/day, increase at 1-week intervals by increments of 50mg/week for the 1st 4 weeks, then increase by 100mg/week for weeks 5–6 to target dose of 400mg/day. Adjunctive therapy: <2yrs: not recommended. 2–16yrs: Initially 1–3mg/kg (max 25mg) per day given in the PM for 1 week, increase at 1–2 week intervals by 1–3mg/kg/day to target range of 5–9mg/kg/day in 2 divided doses. Renal impairment (CrCl <70mL/min): reduce dose by ½. Hemodialysis: may need extra dose.

See Also:

TOPAMAX TABLETS

Pharmacological Class:

Sulfamate.

Warnings/Precautions:

Discontinue if acute myopia and secondary angle-closure glaucoma occur. Hepatic or renal impairment. Kidney stones. Maintain adequate hydration and caloric intake; avoid ketogenic diets. Monitor serum bicarbonate during therapy; consider reducing dose or discontinuing if acidosis occurs. Inborn errors of metabolism, reduced mitochondrial activity: increased risk of hyperammonemia; measure ammonia levels if encephalopathic symptoms occur. Monitor closely for oligohidrosis and hyperthermia (esp. children). Suicidal tendencies (monitor). Avoid abrupt cessation. Fetal toxicity. Labor & delivery. Pregnancy (Cat.D). Nursing mothers.

Interactions:

Contraindicated with metformin during metabolic acidosis condition. Avoid concomitant other carbonic anhydrase inhibitors (eg, zonisamide, acetazolamide, dichlorphenamide). Phenytoin, carbamazepine, valproic acid, lamotrigine reduce topiramate levels. Topiramate reduces valproic acid levels. May increase phenytoin levels. May antagonize digoxin, oral contraceptives, risperidone. CNS depression potentiated with alcohol, other CNS depressants. Hyperammonemia (w/ and w/o encephalopathy) and/or hypothermia possible with valproic acid. Caution with other drugs that interfere with temperature regulation (eg, anticholinergics, carbonic anhydrase inhibitors). Monitor lithium levels with high-dose topiramate.

Adverse Reactions:

Paresthesia, anorexia, weight decrease, fatigue, dizziness, somnolence, nervousness, psychomotor slowing, difficulty with memory, difficulty with concentration/attention, cognitive problems, confusion, mood problems, fever, infection, flushing; kidney stones, hyperchloremic acidosis, hyperammonemia.

Metabolism:

Hepatic (minor).

Elimination:

Renal.

Generic Availability:

YES

How Supplied:

Tabs, caps—60

Sign Up for Free e-newsletters